Cargando…

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model

Previous clinical studies have demonstrated that endotoxin/toll-like receptor 4 (TLR4) signaling is critical in the inflammatory pathways associated with non-alcoholic steatohepatitis (NASH). In human and animal studies, NASH was associated with portal lipopolysaccharide (LPS) and the plasma LPS lev...

Descripción completa

Detalles Bibliográficos
Autores principales:	DOUHARA, AKITOSHI, MORIYA, KEI, YOSHIJI, HITOSHI, NOGUCHI, RYUICHI, NAMISAKI, TADASHI, KITADE, MITSUTERU, KAJI, KOSUKE, AIHARA, YOSUKE, NISHIMURA, NORIHISA, TAKEDA, KOSUKE, OKURA, YASUSHI, KAWARATANI, HIDETO, FUKUI, HIROSHI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270343/ https://www.ncbi.nlm.nih.gov/pubmed/25421042 http://dx.doi.org/10.3892/mmr.2014.2995

Ejemplares similares

Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats
por: Noguchi, Ryuichi, et al.
Publicado: (2020)

Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development
por: Takeda, Kosuke, et al.
Publicado: (2017)

DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis
por: Asada, Kiyoshi, et al.
Publicado: (2016)

Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B
por: Noguchi, Ryuichi, et al.
Publicado: (2017)

Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model
por: Seki, Kenichiro, et al.
Publicado: (2018)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats
por: Nishimura, Norihisa, et al.
Publicado: (2018)

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
por: Asada, Kiyoshi, et al.
Publicado: (2020)

The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure
por: Namisaki, Tadashi, et al.
Publicado: (2010)

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
por: Tsuji, Yuki, et al.
Publicado: (2020)

The Effect of Inflammatory Cytokines in Alcoholic Liver Disease
por: Kawaratani, Hideto, et al.
Publicado: (2013)

Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model
por: Nakanishi, Keisuke, et al.
Publicado: (2019)

Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis
por: Ogawa, Hiroyuki, et al.
Publicado: (2021)

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis
por: Moriya, Kei, et al.
Publicado: (2021)

Association between Equol Production Status and Nonalcoholic Steatohepatitis
por: Akahane, Takemi, et al.
Publicado: (2021)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
por: Moriya, Kei, et al.
Publicado: (2021)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
por: Ozutsumi, Takahiro, et al.
Publicado: (2020)

Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance
por: YOSHIJI, HITOSHI, et al.
Publicado: (2013)

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability
por: Takaya, Hiroaki, et al.
Publicado: (2022)

Glycogenic Hepatopathy in Type 1 Diabetes Mellitus
por: Asada, Shohei, et al.
Publicado: (2017)

Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2020)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
por: Moriya, Kei, et al.
Publicado: (2019)

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019)

Efficacy of Serum Ferritin–Zinc Ratio for Predicting Advanced Liver Fibrosis in Patients with Autoimmune Hepatitis
por: Moriya, Kei, et al.
Publicado: (2023)

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2020)

Spontaneously ruptured hepatocellular carcinoma in Fontan-associated liver disease: A case report
por: Kubo, Takahiro, et al.
Publicado: (2020)

Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa(®) and VIVA(®) Systems
por: Takaya, Hiroaki, et al.
Publicado: (2022)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
por: Takagi, Hirotetsu, et al.
Publicado: (2021)

Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Management of refractory cirrhotic ascites: challenges and solutions
por: Fukui, Hiroshi, et al.
Publicado: (2018)

A Patient with Hepatocellular Carcinoma with Isolated Right Atrial Metastases
por: Takaya, Hiroaki, et al.
Publicado: (2017)

Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis
por: Nishimura, Norihisa, et al.
Publicado: (2021)

The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2023)

The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis
por: Sato, Shinya, et al.
Publicado: (2021)

Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report
por: Mashitani, Tsuyoshi, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jb4fe0sia5bfgkmds47rbh2ve2